Noel G. McElvaney

By Catherine M. Greene and Noel G. McElvaney

Part of the book: Gene Therapy Applications

By Tomás P. Carroll, Catherine A. O’Connor, Emer P. Reeves and Noel G. McElvaney

Part of the book: Chronic Obstructive Pulmonary Disease

By Sanjay H. Chotirmall, Catherine M. Greene, Brian J. Harvey and Noel G. McElvaney

Part of the book: Cystic Fibrosis

By Cormac McCarthy, Ciara A. O’Dwyer, David A. Bergin, Noel G. McElvaney and Emer P. Reeves

Part of the book: COPD Clinical Perspectives

By Tomás P. Carroll, M. Emmet O’Brien, Laura T. Fee, Kevin Molloy, Blair Murray, Seshma Ramsawak, Oisín McElvaney, Catherine O’Connor and Noel G. McElvaney

Part of the book: COPD Clinical Perspectives

By Michelle M. White, Fatma Gargoum, Niall Browne, Killian Hurley, Noel G. McElvaney and Emer P. Reeves

Despite tremendous recent advances in our understanding of the molecular and cellular basis of cystic fibrosis (CF), there remains a paradox of why recruited neutrophils fail to eradicate bacterial infections in the airways of individuals with CF. The focus of this chapter is on new research authenticating the CF neutrophil as a key player in disease pathogenesis. Studies specifying intrinsic abnormalities due to a lack of cystic fibrosis transmembrane conductance regulator (CFTR) function, along with reports indicating reprogrammed cell activity secondary to chronic bacterial infection and inflammation, will be discussed.

Part of the book: Cystic Fibrosis in the Light of New Research

By Cormac McCarthy, Orla O’Carroll, Alessandro N. Franciosi and Noel G. McElvaney

Cystic fibrosis (CF) is a multisystem disorder with a significantly shortened life expectancy with the major cause of mortality related to lung disease. Inflammation is seen in the CF airways from a very early age and contributes significantly to symptoms and disease progression. As the condition worsens over time, lung function declines, usually measured by Forced Expiratory Volume in 1 second (FEV1)% predicted, and extra-pulmonary complications often manifest. While the life expectancy in CF is still short, the median age of death and predicted survival age are continually increasing. Therapeutic interventions for CF have improved significantly in the last 20 years and now there are targeted therapies towards specific elements in CF that may impact upon exacerbation frequency, symptoms, and eventually mortality due to lung disease.

Part of the book: Cystic Fibrosis in the Light of New Research